The novel proteasome inhibitor BSc2118 protects against cerebral ischaemia through HIF1A accumulation and enhanced angioneurogenesis

Brain

Volumn 135, Issue 11, 2012, Pages 3282-3297

  Doeppner, Thorsten R ^a,b   Mlynarczuk Bialy, Izabela ^c   Kuckelkorn, Ulrike ^d   Kaltwasser, Britta ^a,b   Herz, Josephine ^a   Hasan, Mohammad R ^a   Hermann, Dirk M ^a   Bähr, Mathias ^b,e  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e Deutsche Forschungsgemeinschaft   (Germany)

Author keywords

cerebral ischaemia; neurogenesis; neuroprotective agents; neuroregeneration; thrombolytic therapy

Indexed keywords

BSC2118; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEASOME INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN ISCHEMIA; CONTROLLED STUDY; ENZYME ACTIVITY; MALE; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; WESTERN BLOTTING; ZYMOGRAPHY;

EID: 84870226746     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aws269     Document Type: Review

References (51)

1. Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O. Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat Med 2002; 8: 963-70.
2. Berti R, Williams AJ, Velarde LC, Moffett JR, Elliott PJ, Adams J, et al. Effect of the proteasome inhibitor MLN519 on the expression of inflammatory molecules following middle cerebral artery occlusion and reperfusion in the rat. Neurotox Res 2003; 5: 505-14.
3. Braun HA, Umbreen S, Groll M, Kuckelkorn U, Mlynarczuk I, Wigand ME, et al. Tripeptide mimetics inhibit the 20S proteasome by covalent bonding to the active threonines. J Biol Chem 2005; 280: 28394-401.
4. Buchan AM, Li H, Blackburn B. Neuroprotection achieved with a novel proteasome inhibitor which blocks NF-kappaB activation. Neuroreport 2000; 11: 427-30.
5. Candelario-Jalil E, Yang Y, Rosenberg GA. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischaemia. Neuroscience 2009; 158: 983-94.
6. Chavez JC, LaManna JC. Activation of hypoxia-inducible factor-1 in the rat cerebral cortex after transient global ischaemia: potential role of insulin-like growth factor-1. J Neurosci 2002; 22: 8922-31.
7. Chiba Y, Sasayama T, Miyake S, Koyama J, Kondoh T, Hosoda K, et al. Anti-VEGF receptor antagonist (VGA1155) reduces infarction in rat permanent focal brain ischaemia. Kobe J Med Sci 2008; 54: E136-46. (Pubitemid 352039825)
8. Copin JC, Bengualid DJ, Da Silva RF, Kargiotis O, Schaller K, Gasche Y. Recombinant tissue plasminogen activator induces blood-brain barrier breakdown by a matrix metalloproteinase-9-independent pathway after transient focal cerebral ischaemia in mouse. Eur J Neurosci 2011; 34: 1085-92.
9. Crome O, Doeppner TR, Schwarting S, Muller B, Bahr M, Weise J. Enhanced poly(ADP-ribose) polymerase-1 activation contributes to recombinant tissue plasminogen activator-induced aggravation of ischaemic brain injury in vivo. J Neurosci Res 2007; 85: 1734-43.
10. Cunningham LA, Candelario K, Li L. Roles for HIF-1alpha in neural stem cell function and the regenerative response to stroke. Behav Brain Res 2012; 227: 410-17.
11. Dahlmann B. Role of proteasomes in disease. BMC Biochem 2007; 8 (Suppl 1): S3.
12. Di Napoli M, McLaughlin B. The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors. Curr Opin Investig Drugs 2005; 6: 686-99.
13. Dirnagl U. Bench to bedside: the quest for quality in experimental stroke research. J Cereb Blood Flow Metab 2006; 26: 1465-78.
14. Doeppner TR, Grune T, de Groot H, Rauen U. Cold-induced apoptosis of rat liver endothelial cells: involvement of the proteasome. Transplantation 2003; 75: 1946-53.
15. Doeppner TR, Kaltwasser B, Elali A, Zechariah A, Hermann DM, Bähr M. Acute hepatocyte growth factor treatment induces long-Term neuroprotection and stroke recovery via mechanisms involving neural precursor cell proliferation and differentiation. J Cereb Blood Flow Metab 2011a; 5: 1251-62.
16. Doeppner TR, El Aanbouri M, Dietz GP, Weise J, Schwarting S, Bähr M. Transplantation of TAT-Bcl-xL-Transduced neural precursor cells: long-Term neuroprotection after stroke. Neurobiol Dis 2010; 40: 265-76.
17. Doeppner TR, Bretschneider E, Doehring M, Segura I, Senturk A, Acker-Palmer A, et al. Enhancement of endogenous neurogenesis in ephrin-B3 deficient mice after transient focal cerebral ischaemia. Acta Neuropathol 2011b; 122: 429-42.
18. Elliott PJ, Ross JS. The proteasome: a new target for novel drug therapies. Am J Clin Pathol 2001; 116: 637-46.
19. Ge P, Luo Y, Liu CL, Hu B. Protein aggregation and proteasome dysfunction after brain ischaemia. Stroke 2007; 38: 3230-6. (Pubitemid 350175742)
20. Goldberg AL. Functions of the proteasome: the lysis at the end of the tunnel. Science 1995; 268: 522-3.
21. Greenberg DA, Jin K. From angiogenesis to neuropathology. Nature 2005; 438: 954-9. (Pubitemid 43093961)
22. Henninger N, Sicard KM, Bouley J, Fisher M, Stagliano NE. The proteasome inhibitor VELCADE reduces infarction in rat models of focal cerebral ischaemia. Neurosci Lett 2006; 398: 300-5. (Pubitemid 43673703)
23. Hermann DM, Chopp M. Promoting brain remodelling and plasticity for stroke recovery: therapeutic promise and potential pitfalls of clinical translation. Lancet Neurol 2012; 11: 369-80.
24. Hess DC, Borlongan CV. Stem cells and neurological diseases. Cell Prolif 2008; 41 (Suppl 1): 94-114.
25. Kilic E, Bähr M, Hermann DM. Effects of recombinant tissue plasminogen activator after intraluminal thread occlusion in mice: role of hemodynamic alterations. Stroke 2001; 32: 2641-7. (Pubitemid 33055319)
26. Kilic E, Kilic U, Bähr M, Hermann DM. Tissue plasminogen activator-induced ischaemic injury is reversed by NMDA antagonist MK-801 in vivo. Neurodegener Dis 2005a; 2: 49-55.
27. Kilic E, Kilic U, Matter CM, Lüscher TF, Bassetti CL, Hermann DM. Aggravation of focal cerebral ischaemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor but does not depend on endothelial NO synthase. Stroke 2005b; 36: 332-6. (Pubitemid 40170818)
28. Kukan M. Emerging roles of proteasomes in ischaemia-reperfusion injury of organs. J Physiol Pharmacol 2004; 55: 3-15. (Pubitemid 38524210)
29. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695-703.
30. Mazumdar J, O'Brien WT, Johnson RS, LaManna JC, Chavez JC, Klein PS, Simon MC. O2 regulates stem cells through Wnt/beta-catenin signalling. Nat Cell Biol 2010; 12: 1007-13.
31. Noll T, de Groot H, Sies H. Distinct temporal relation among oxygen uptake, malondialdehyde formation, and low-level chemiluminescence during microsomal lipid peroxidation. Arch Biochem Biophys 1987; 252: 284-91.
32. Petroski MD. The ubiquitin system, disease, and drug discovery. BMC Biochem 2008; 9 (Suppl 1): S7.
33. Phillips JB, Williams AJ, Adams J, Elliott PJ, Tortella FC. Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischaemia. Stroke 2000; 31: 1686-93.
34. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-17.
35. Rivett AJ. Proteasomes: multicatalytic proteinase complexes. Biochem J 1993; 291 (Pt 1): 1-10. (Pubitemid 23107740)
36. Rogalewski A, Schneider A, Ringelstein EB, Schabitz WR. Toward a multimodal neuroprotective treatment of stroke. Stroke 2006; 37: 1129-36.
37. Ruschak AM, Slassi M, Kay LE, Schimmer AD. Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst 2011; 103: 1007-17.
38. Shi H. Hypoxia inducible factor 1 as a therapeutic target in ischaemic stroke. Curr Med Chem 2009; 16: 4593-600.
39. Sinn DI, Lee ST, Chu K, Jung KH, Kim EH, Kim JM, et al. Proteasomal inhibition in intracerebral hemorrhage: neuroprotective and anti-inflammatory effects of bortezomib. Neurosci Res 2007; 58: 12-18.
40. Sterz J, Jakob C, Kuckelkorn U, Heider U, Mieth M, Kleeberg L, et al. BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma. Eur J Haematol 2010; 85: 99-107.
41. Su EJ, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J, et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischaemic stroke. Nat Med 2008; 14: 731-7.
42. Sun HL, Liu YN, Huang YT, Pan SL, Huang DY, Guh JH, et al. YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia. Oncogene 2007; 26: 3941-51.
43. Tsai YW, Yang YR, Wang PS, Wang RY. Intermittent hypoxia after transient focal ischaemia induces hippocampal neurogenesis and c-Fos expression and reverses spatial memory deficits in rats. PLoS One 2011; 6: e24001.
44. Wacker BK, Park TS, Gidday JM. Hypoxic preconditioning-induced cerebral ischaemic tolerance: role of microvascular sphingosine kinase 2. Stroke 2009; 40: 3342-8.
45. Williams AJ, Hale SL, Moffett JR, Dave JR, Elliott PJ, Adams J, et al. Delayed treatment with MLN519 reduces infarction and associated neurologic deficit caused by focal ischaemic brain injury in rats via antiinflammatory mechanisms involving nuclear factor-kappaB activation, gliosis, and leukocyte infiltration. J Cereb Blood Flow Metab 2003; 23: 75-87.
46. Xiong Y, Mahmood A, Chopp M. Angiogenesis, neurogenesis and brain recovery of function following injury. Curr Opin Investig Drugs 2010; 11: 298-308.
47. Yan J, Zhou B, Taheri S, Shi H. Differential effects of HIF-1 inhibition by YC-1 on the overall outcome and blood-brain barrier damage in a rat model of ischemic stroke. PLoS One 2011; 6: e27798.
48. Zhang L, Zhang ZG, Zhang RL, Lu M, Adams J, Elliott PJ, et al. Postischaemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischaemia. Stroke 2001; 32: 2926-31.
49. Zhang L, Schallert T, Zhang ZG, Jiang Q, Arniego P, Li Q, et al. A test for detecting long-Term sensorimotor dysfunction in the mouse after focal cerebral ischaemia. J Neurosci Methods 2002; 117: 207-14.
50. Zhang L, Zhang ZG, Liu X, Hozeska A, Stagliano N, Riordan W, et al. Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator. Thromb Haemost 2006; 95: 166-73.
51. Zhang L, Zhang ZG, Buller B, Jiang J, Jiang Y, Zhao D, et al. Combination treatment with VELCADE and low-dose tissue plasminogen activator provides potent neuroprotection in aged rats after embolic focal ischaemia. Stroke 2010; 41: 1001-7.